Company Description
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases.
The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.
Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure.
The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy.
Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.
| Country | United States |
| Founded | 1997 |
| IPO Date | Apr 29, 2004 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 423 |
| CEO | Robert Blum |
Contact Details
Address: 350 Oyster Point Boulevard South San Francisco, California 94080 United States | |
| Phone | 650 624 3000 |
| Website | cytokinetics.com |
Stock Details
| Ticker Symbol | CYTK |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001061983 |
| CUSIP Number | 23282W605 |
| ISIN Number | US23282W6057 |
| Employer ID | 94-3291317 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Robert I. Blum | Chief Executive Officer, President and Director |
| Robert C. Wong | Vice President and Chief Accounting Officer |
| Dr. Fady Ibraham Malik FACC, M.D., Ph.D. | Executive Vice President of Research and Development |
| Andrew M. Callos | Executive Vice President and Chief Commercial Officer |
| Dr. James A. Spudich Ph.D. | Co-Founder and Member of Scientific Advisory Board |
| Sung H. Lee | Executive Vice President and Chief Financial Officer |
| Jeff Lotz | Vice President of Sales and Operations |
| Matt Yang | Vice President of Corporate Finance and Financial Planning and Analysis |
| Kari K. Loeser J.D. | Vice President and Chief Compliance Officer |
| John O. Faurescu Esq. | Vice President, Associate General Counsel and Corporate Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 19, 2024 | 8-K | Current Report |
| Nov 18, 2024 | 144 | Filing |
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | 144 | Filing |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 7, 2024 | 10-Q | Quarterly Report |
| Nov 7, 2024 | 8-K | Current Report |
| Nov 4, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |